Minoxidil

The other pillar of hair retention — topical foam/solution OTC, and increasingly low-dose ORAL minoxidil prescribed off-label by dermatologists, which is where the biohacker conversation has moved.

Minoxidil was a blood-pressure drug before anyone noticed it grew hair. It opens potassium channels in vascular smooth muscle, widening blood vessels — but the hair effect is not simply better blood flow. It lengthens the growth phase of the hair cycle and pushes resting follicles back into growing, which is why the first visible event is often shedding: old hairs are pushed out as new ones start underneath. Unlike finasteride it does nothing about DHT, so it is not limited to androgen-driven loss and the two are commonly combined. That is not the same as working regardless of cause: scarring alopecias and loss from nutritional, endocrine, inflammatory, medication-related or postpartum causes need their own diagnosis, and efficacy depends on which one you actually have.

Topical: proven, modest, decades of data; works on a hair-cycle timescale (judge at 6-12 months, expect an early shed). Oral low-dose: growing dermatology literature reports stronger effect than topical with acceptable tolerability in most — but it is off-label, and the trials are smaller and shorter than finasteride's.

• Topical minoxidil is FDA-approved for pattern hair loss in men and women, with randomised trials supporting increased hair count over four to six months. Effect sizes are modest but real and replicated.
• Oral low-dose minoxidil is used off-label in dermatology. A 24-week randomised trial enrolling 90 men found it was NOT superior to topical 5% minoxidil on terminal hair density — comparable, not stronger, which is the opposite of how it is usually described. Adherence is easier; systemic effects are the trade-off.
• Response is partial and variable. A substantial minority of users see little benefit, and a common explanation for topical non-response is low activity of the enzyme in the scalp that converts minoxidil to its active form.
• The 5% formulation outperforms 2% in men. In women, 5% foam once daily performs comparably to 2% solution twice daily with better tolerability.

Topical absorption is low but not zero, and rises on irritated or freshly microneedled skin. The active form is minoxidil sulfate, produced by a sulfotransferase enzyme in the follicle whose activity varies a lot between people — this is the leading explanation for non-response and is the basis of the tests some clinics sell. Effects take three to six months to appear and twelve months for a fair judgement. Benefit depends entirely on continued use; stopping returns the scalp to its untreated trajectory over three to six months.

Topical: scalp irritation, unwanted facial hair with drift. Oral: it is a blood-pressure drug at heart — fluid retention, ankle swelling, reflex tachycardia, body-wide hair growth; rare pericardial effusion reports at higher doses are why dermatologists start low. Cats die from exposure to it — genuinely.

• Anyone with cardiovascular disease considering the oral form without a prescriber
• Anyone pregnant or breastfeeding
• Anyone with a scalp condition or broken skin, until it is treated
• Anyone whose hair loss has not been diagnosed — several causes need a different treatment entirely

• Other blood-pressure medication — additive hypotension, which matters for oral minoxidil rather than topical.
• Tretinoin and microneedling — both substantially increase absorption, which raises both effect and systemic exposure.
• Alcohol-based scalp products, which compound irritation.
• Oral minoxidil in anyone with existing heart disease requires a clinician, not a self-directed decision.
• CATS AND DOGS — minoxidil is severely toxic to pets and this is not a footnote. Amounts as small as residue on skin, bedding or a spill have proved fatal; in one series of 62 symptomatic cats, eight died. Any suspected exposure needs an immediate call to a veterinary poison service.

• Photographs under consistent lighting, because slow change is invisible day to day.
• The expected early shed at weeks 2-8 — knowing it is coming prevents people quitting at the exact moment the drug started working.
• Scalp irritation and contact dermatitis, most often from the propylene glycol in solutions rather than the drug.
• Even topical use has systemic warnings on the label: chest pain, rapid heartbeat, faintness or dizziness, sudden unexplained weight gain, and swelling of hands or feet all mean stop and get advice.
• For oral use specifically: the oral label carries a BOXED WARNING for pericardial effusion — fluid around the heart, which can progress to tamponade — and for worsening angina. Effusion occurred in roughly 3% of non-dialysis patients in the blood-pressure experience. Hair-loss use is off-label and its long-term cardiovascular safety at low dose is genuinely unestablished. Blood pressure, heart rate, ankle swelling and any breathlessness or chest pain all matter.
• Unwanted facial hair, particularly on oral use and particularly in women.

Hair maintained by minoxidil is lost over roughly three to six months after stopping, and the shedding during that period can feel dramatic because it is losing the added hairs relatively quickly. There is no withdrawal syndrome from topical use. Stopping oral minoxidil should involve the prescriber who started it. The rebound-hypertension concern comes from its use as a blood-pressure drug, and there is no evidence it applies to low-dose use in people with normal blood pressure. The practical point is that this is a maintenance treatment: the results last as long as the use does.

US: topical is OTC; oral is prescription-only, prescribed off-label.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• Evaluating the efficacy and safety of combined microneedling therapy versus topical Minoxidil in androgenetic alopecia: a systematic review and meta-analysis
  Arch Dermatol Res, 2025
• Efficacy and safety of combinational therapy using topical minoxidil and microneedling for the treatment of androgenetic alopecia: a systematic review and meta-analysis
  Arch Dermatol Res, 2023
• The Efficacy and Safety of Finasteride Combined with Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-analysis
  Aesthetic Plast Surg, 2020

• Minoxidil: a comprehensive reviewJ Dermatolog Treat · 2022
• Oral minoxidil treatment for hair loss: A review of efficacy and safetyJ Am Acad Dermatol · 2021
• Minoxidil: mechanisms of action on hair growthBr J Dermatol · 2004
• Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical TrialJAMA Dermatol · 2024
• Minoxidil and its use in hair disorders: a reviewDrug Des Devel Ther · 2019
• Summation and recommendations for the safe and effective use of topical and oral minoxidilJ Am Acad Dermatol · 2025
• MinoxidilDermatol Clin · 1987
• MinoxidilSouth Med J · 1980
• A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in menJ Am Acad Dermatol · 2002
• Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymesDermatol Ther · 2019
• Efficacy and safety of oral minoxidil versus topical solution in androgenetic alopecia: a meta-analysis of randomized clinical trialsInt J Dermatol · 2025
• Injectable Minoxidil for Hair Loss Disorders: A Systematic ReviewJ Drugs Dermatol · 2024